Cancer cells have evolved sophisticated strategies to evade the immune system, prolonging their survival and growth. They have also developed survival tactics to resist immune checkpoint inhibition ...
Longitudinal tumor-informed cfDNA whole genome sequencing to capture residual disease during neoadjuvant immune checkpoint inhibition in resectable gastroesophageal cancer. Precision medicine research ...
Anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma (nccRR): Preliminary results from an exploratory prospective multicentre ...
NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (INKT) cell therapies to treat cancer and other immune-mediated diseases, today announced the publication of a case report in ...
This article is based on a poster originally authored by Smith Frank, Boute Melodie, Ruez Richard, Amandine Gerstenberg and Ramos Corinne. This poster is being hosted on this website in its raw form, ...
Biagio Ricciuti, MD, PhD, Giuseppe Lamberti, MD, PhD, Sreekar R. Puchala, PhD, Navin R. Mahadevan, MD, PhD, Jia-Ren Lin, PhD, Joao V. Alessi, MD, Alexander Chowdhury ...
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to enhancing survival for ...
Checkpoint inhibitor therapies can be thought of as the molecular “brake release” for the immune system. These drugs eliminate the protein barriers that block the immune system from recognizing and ...
IMMUNOLIFE, a Phase 2 randomized exploratory study, will evaluate the potential of MaaT033 in combination with Cemiplimab versus Best Investigator Choice (i.e.: second line) in enhancing disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results